BSE filing, NSE: MODIS. Summary written from the filing by ALFA Finder's alert engine.
Modis Navnirman Ltd: key numbers
- Share price
- ₹383.05
- Market cap
- ₹750.4 Cr
- Revenue (annual)
- ₹189.3 Cr
- Net profit (annual)
- ₹29.18 Cr
- P/E (TTM)
- 20.7×Sector 34.0×
- Promoter holding
- 63.79%+0.00% QoQ
- FII holding
- 12.27%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Modis Navnirman Ltd
All →Modis Navnirman Earnings Call Transcript: Key Takeaways
Management reports strong H1 performance driven by high-velocity redevelopment projects and successful new launches.
- Call
- Guides 57% growth
Modis Navnirman Investor Presentation: Key Takeaways
H1 FY27 revenue ₹127.64 Cr (+53% YoY), EBITDA ₹26.19 Cr (+63%), PAT ₹19.08 Cr (+59%). Redevelopment-led Mumbai pipeline; 10.50 lakh sq ft potential launches.
Modis Navnirman Results Update
Modis Navnirman reported H1 FY27 revenue of ₹127.64 Cr, up 53%, and PAT of ₹19.08 Cr, up 59%, via a press release. The release also cites 78,560 sq ft of sales and a new redevelopment project.
Modis Navnirman Q2 FY27 Results: Net Profit ₹10.5 Cr, Up 101.9% YoY
Modis Navnirman Ltd reported revenue from operations of ₹69.4 Cr (+83.6% YoY) and net profit of ₹10.5 Cr (+101.9% YoY) for Q2 FY27.
- Key figure
- Net profit ₹10.5 Cr · +101.9% YoY
Modis Navnirman Board Meeting Date
Modis Navnirman Limited intimated a board meeting on 24 Oct 2026 to consider unaudited half-yearly financial results. No monetary value is disclosed.
Modis Navnirman Earnings Call Transcript: Key Takeaways
Modis Navnirman reported solid Q1 FY27 growth despite temporary margin pressure from the Russia-Ukraine war and rising material costs. Management remains optimistic about Mumbai's re-development market with 11 upcoming projects and high pre-sales velocity.
Other other announcement announcements
All →Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.
Shriram Asset Management Company Other Announcement
Shriram AMC filed ICRA's quarterly monitoring agency report on preferential issue proceeds. Utilisation is in line with the offer objects, with no deviation reported.
Jhandewalas Foods Other Announcement
Jhandewalas Foods filed its quarterly shareholding pattern for the period ended September 30, 2026. The filing records holdings by category and contains no transaction or money event.
Avience Biomedicals Other Announcement
Avience Biomedicals confirmed corporate governance compliance is not applicable, as it is SME-listed on NSE Emerge. No quarterly governance report is required for September 2026.